戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 sociated with germline RET mutations causing multiple endocrine neoplasia type 2.
2  of oncogenic Ret receptor in a fly model of Multiple Endocrine Neoplasia Type 2.
3 or cure the endocrinopathies associated with multiple endocrine neoplasia type 2.
4 among patients with Hirschsprung disease and multiple endocrine neoplasia type 2.
5 evelopment of the inherited cancer syndrome, multiple endocrine neoplasia type 2.
6 ch encodes a receptor tyrosine kinase, cause multiple endocrine neoplasia type 2.
7 agement of phaeochromocytoma associated with multiple endocrine neoplasia type 2.
8 ly active oncogenic RET, were found to cause multiple endocrine neoplasia type 2, a dominant inherite
9 sing a Ret-kinase-driven Drosophila model of multiple endocrine neoplasia type 2 and kinome-wide drug
10 n-based study compiled data on patients with multiple endocrine neoplasia type 2 from 30 academic med
11 ast year addressing the surgical approach to multiple endocrine neoplasia type 2 in the pediatric pop
12  phaeochromocytoma (MIM No 171300) occurs in multiple endocrine neoplasia type 2 (MEN 2) (MIM No 1714
13                                              Multiple endocrine neoplasia type 2 (MEN 2) is an autoso
14                                              Multiple endocrine neoplasia type 2 (MEN 2) is an inheri
15                                              Multiple endocrine neoplasia type 2 (MEN 2) syndrome is
16 sible for the familial tumor syndrome called multiple endocrine neoplasia type 2 (MEN 2) that include
17 ase underlies the genesis and progression of multiple endocrine neoplasia type 2 (MEN 2), a dominantl
18 ery cell of the body) mutations in RET cause multiple endocrine neoplasia type 2 (MEN 2), an inherite
19 ibility are von Hippel-Lindau disease (VHL), multiple endocrine neoplasia type 2 (MEN 2), the newly d
20 to-oncogene are tumorigenic in patients with multiple endocrine neoplasia type 2 (MEN 2).
21 th the dominantly inherited cancer syndromes multiple endocrine neoplasia type 2 (MEN 2).
22 s patients with von Hippel-Lindau disease or multiple endocrine neoplasia type 2 (MEN-2), is hindered
23                                Patients with multiple endocrine neoplasia type 2 (MEN2) have mutation
24  and nonmedullary thyroid cancers related to multiple endocrine neoplasia type 2 (MEN2), Cowden syndr
25  thyroid carcinoma (MTC) and pathogenesis of multiple endocrine neoplasia type 2 (MEN2).
26  kinase lead to the familial cancer syndrome multiple endocrine neoplasia type 2 (MEN2).
27 logy analogous to that seen in patients with multiple endocrine neoplasia type 2 (MEN2).
28 and low toxicity in Drosophila and mammalian multiple endocrine neoplasia type 2 models.
29 r, the other major neoplasia associated with multiple endocrine neoplasia type 2, phaeochromocytoma,
30                             The treatment of multiple endocrine neoplasia type 2-related phaeochromoc
31 d with cystic fibrosis, hemochromatosis, and multiple endocrine neoplasia, type 2, respectively.
32 of medullary thyroid cancer in patients with multiple endocrine neoplasia type 2 syndrome has demonst
33  remaining 25% are hereditary and related to multiple endocrine neoplasia type 2 syndrome.
34 tential therapeutic agents for patients with multiple endocrine neoplasia type 2 tumors because both,
35                                              Multiple endocrine neoplasia type 2, von Hippel-Lindau d
36 somal dominantly inherited cancer syndromes, multiple endocrine neoplasia type 2, von Hippel-Lindau d
37 d for 84% of the patients; the other 16% had multiple endocrine neoplasia type 2, von Recklinghausen'
38                           1210 patients with multiple endocrine neoplasia type 2 were included in our
39 gical intervention in children affected with multiple endocrine neoplasia type 2 will lead to better

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。